LONDON (ShareCast) - (Sharecast News) - Roquefort Therapeutics revealed on Monday that interim managing director Darrin Disley had acquired 5.0m ordinary shares in the London-listed material biotech company.
Disley, who joined Roquefort in September 2022, purchased the shares on Friday at an average price of 1.70p each, for a total value of £85,000.

As a result of the transaction, Disley now holds a beneficial interest in 7.02m ordinary Roquefort shares, representing approximately 4.46% of Roquefort's issued share capital.

As of 1530 GMT, Roquefort shares were up 1.29% at 1.92p.

Reporting by Iain Gilbert at Sharecast.com

Top Director Buys

Roquefort Therapeutics (ROQ)
Director name: Disley,Dr Darrin
Amount purchased: 5,000,000 @ 170.00p
Value: £85,000

Mobius Investment Trust (MMIT)
Director name: Dyer Bartlett ,Diana
Amount purchased: 21,469 @ 137.50p
Value: £29,519.88

Grainger (GRI)
Director name: Fraser,Simon
Amount purchased: 15,000 @ 183.00p
Value: £27,450.00

Paypoint (PAY)
Director name: Harding,Rob
Amount purchased: 1,924 @ 519.00p
Value: £9,985.56



Top Director Sells

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE